Prelude Therapeutics
Clinical trials sponsored by Prelude Therapeutics, explained in plain language.
-
Experimental cancer pill targets rare mutation, but trial halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in 42 people with advanced solid tumors that have a SMARCA4 mutation. The goal was to check safety, find the right dose, and see if it shrinks tumors. However, the trial was terminated, so full results are not…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Experimental combo for rare Gene-Mutated cancers halted early
Disease control TerminatedThis study tested a new drug (PRT3789) combined with the immunotherapy pembrolizumab in people with advanced or spreading solid tumors that have a specific genetic change called SMARCA4 mutation. The goal was to see if the combination was safe and could shrink tumors. Only 6 part…
Phase: PHASE2 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC